Vertex will own exclusive license for Treefrog’s cell manufacturing technology, C-Stem
As per the agreement, TreeFrog will receive $25M as upfront payment, ~$540M for clinical, regulatory and commercial milestones on up to two products, ~215M as milestone payment on development of fully differentiated Islet cells, an equity investment from Vertex and a tiered single digit Royalties; Vertex to also fund future R&D cost related to collaboration
C-Stem imitates natural microenvironment allowing cell to grow exponentially in 3D and Vertex plans to use C-Stem to scale up production of Insulin producing Pancreatic Islet cells and deliver it to T1D patients
Ref: Vertex | Image: Vertex
Related News:- Vertex to Acquire Alpine Immune Sciences for ~$4.9B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
